zydus lifesciences: USFDA approves Zydus Lifesciences to market generic Micafungin injection

0
0


Zydus Lifesciences said Wednesday it has received the final nod from the US health regulator to market its generic Micafungin injection, which is used to treat a variety of fungal infections.

The United States Food and Drug Administration (USFDA) has given its approval to market Micafungin for Injection, 50 mg/vial and 100 mg/vial, single-dose vials, Zydus Lifesciences Ltd said in an exchange filing.

Shares of Zydus Lifesciences were up about a percent to 417.25 rupees on the BSE.

Micafungin for injection is also used to prevent fungal infections in patients who are having a stem cell transplant. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India, the company said.

Micafungin for injection had annual sales of $99 million in the US, according to IQVIA MAT August 2022 data.

.



Source link